Recent public disclosures highlight the company's financial challenges, strategic partnership activities, and corporate actions such as a reverse stock split.

• BioForce Nanosciences Holdings announced a 1-for-5 reverse stock split effective February 28, 2020 [N3].
• In June 2021, BioForce Nanosciences signed a memorandum of understanding with Element Global, Inc. (ELGL), indicating potential strategic collaboration [N1].
• Element Acquisition Corporation announced the formation of an investment committee in June 2020, which may relate to the company's investment or strategic activities [N2].
• The company reported no revenue and no sales of its 'BioForce Eclipse' supplement product in 2024 and 2025, with a net loss of approximately $1.29 million in 2025 [S1].
• As of December 31, 2025, the company had only $786 in cash against current liabilities exceeding $619,000, raising substantial doubt about its ability to continue as a going concern [S1].

Potential exists if the company successfully executes its business plan to generate revenues from its natural vitamin and supplement products. Strategic partnerships, such as the MOU with Element Global, may provide avenues for growth or market access. Management's commitment to securing additional funding could support operational continuity and development.

The company has reported no revenue in recent years and significant net losses, with a substantial accumulated deficit. Liquidity is critically low, with current liabilities far exceeding current assets. There is substantial doubt about the company's ability to continue as a going concern without additional financing. Failure to raise capital or generate sales could lead to cessation of operations or significant restructuring.

The company operates in the nutritional supplements sector, which is competitive and fragmented. There is no disclosed information indicating proprietary technology, strong brand recognition, or significant barriers to entry that would constitute a durable competitive advantage. The lack of recent revenue and product sales further limits visibility into any moat.

• Going Concern Risk: The company has minimal cash and significant liabilities, raising substantial doubt about its ability to continue operations without additional financing [S1].
• Revenue Generation Risk: No revenue was reported in 2024 and 2025, and no sales of the company's supplement product occurred during these periods, indicating challenges in market acceptance or execution [S1].
• Liquidity Risk: Liquidity ratios are effectively zero, reflecting an inability to cover current liabilities with current assets, which may impair operational capabilities [S1].
• Dependence on Financing: The company is dependent on raising additional debt or equity financing and has an oral commitment from the Chairman to provide funds, but success is uncertain [S1].

• BioForce Nanosciences Holdings, Inc. is a company focused on becoming a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages aimed at promoting a healthier lifestyle for active individuals across all age ranges [S1].
• As of December 31, 2025, the company had total assets of $786 and total liabilities of $619,329, resulting in a working capital deficit of $618,543 [S1].
• The company reported a net loss of $1,291,951 for the year ended December 31, 2025, which included a loss on liability settlement of approximately $801,193 [S1].
• Revenues for the years ended December 31, 2025 and 2024 were zero, with no unit sales of its 'BioForce Eclipse' supplement product during those periods [S1].
• General and administrative expenses were approximately $66,951 for the year ended December 31, 2025, slightly lower than the prior year [S1].
• The company has an accumulated deficit exceeding $162 million as of December 31, 2025 [S1].
• Liquidity ratios as of December 31, 2025, show a current ratio and cash ratio effectively at zero, reflecting very limited cash and current assets relative to liabilities [S1].
• The company is dependent on additional debt and equity financing to continue operations and implement its business plan; management has an oral commitment from the Chairman to advance funds as necessary for the next 12 months [S1].
• BioForce Nanosciences announced a 1-for-5 reverse stock split effective February 28, 2020 [N3].
• In June 2021, BioForce Nanosciences signed a memorandum of understanding (MOU) with Element Global, Inc. (ELGL) [N1].
• Element Acquisition Corporation announced the formation of an investment committee in June 2020, which may be related to the company's strategic partnerships [N2].